JP2007513967A - 変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物 - Google Patents

変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物 Download PDF

Info

Publication number
JP2007513967A
JP2007513967A JP2006544002A JP2006544002A JP2007513967A JP 2007513967 A JP2007513967 A JP 2007513967A JP 2006544002 A JP2006544002 A JP 2006544002A JP 2006544002 A JP2006544002 A JP 2006544002A JP 2007513967 A JP2007513967 A JP 2007513967A
Authority
JP
Japan
Prior art keywords
inhibitor
tyrosine kinase
receptor tyrosine
mutant receptor
cdk4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006544002A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007513967A5 (https=
Inventor
ロジャー ブリーセウィッツ，
Original Assignee
セラヴァンス， インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セラヴァンス， インコーポレーテッド filed Critical セラヴァンス， インコーポレーテッド
Publication of JP2007513967A publication Critical patent/JP2007513967A/ja
Publication of JP2007513967A5 publication Critical patent/JP2007513967A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2006544002A 2003-12-11 2004-12-09 変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物 Withdrawn JP2007513967A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52861703P 2003-12-11 2003-12-11
PCT/US2004/041333 WO2005058341A2 (en) 2003-12-11 2004-12-09 Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases

Publications (2)

Publication Number Publication Date
JP2007513967A true JP2007513967A (ja) 2007-05-31
JP2007513967A5 JP2007513967A5 (https=) 2008-01-31

Family

ID=34699881

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006544002A Withdrawn JP2007513967A (ja) 2003-12-11 2004-12-09 変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物

Country Status (4)

Country Link
US (1) US20050171182A1 (https=)
EP (1) EP1699477A2 (https=)
JP (1) JP2007513967A (https=)
WO (1) WO2005058341A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016069348A (ja) * 2014-09-30 2016-05-09 学校法人近畿大学 慢性骨髄性白血病の治療用組成物

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE302771T1 (de) * 2001-12-27 2005-09-15 Theravance Inc Indolinon-derivative als protein-kinasehemmer
CA2561516A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
DE102004025726B4 (de) * 2004-05-26 2006-07-06 Roder, Hanno, Dr. Verwendung eines spezifischen K252a-Derivats zur Verhinderung oder Behandlung der Alzheimerschen Krankheit
US20060275365A1 (en) * 2005-06-07 2006-12-07 Thomas Backensfeld Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl) [4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof
US20130210034A1 (en) * 2005-11-04 2013-08-15 Beckman Coulter, Inc. Complex phosphoprotein activation profiles
WO2008076394A1 (en) * 2006-12-14 2008-06-26 Tautatis, Inc. Compositions and methods for the treatment of cancer
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
EP2483406A2 (en) 2009-09-30 2012-08-08 President and Fellows of Harvard College Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products
US9867825B2 (en) * 2012-12-20 2018-01-16 Novartis Ag Pharmaceutical combination comprising binimetinib
US11633401B2 (en) 2018-07-06 2023-04-25 Memorial Sloan Kettering Cancer Center Combination therapy with MEK inhibitor and CDK4/6 inhibitor to treat pancreatic cancer

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN164232B (https=) * 1986-04-11 1989-02-04 Hoechst India
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5525625A (en) * 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
US5733920A (en) * 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
US5821072A (en) * 1996-02-20 1998-10-13 Sloan-Kettering Institute For Cancer Research Combinations of PKC inhibitors and therapaeutic agents for treating cancers
US5849733A (en) * 1996-05-10 1998-12-15 Bristol-Myers Squibb Co. 2-thio or 2-oxo flavopiridol analogs
US6498163B1 (en) * 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
WO1998037881A1 (en) * 1997-02-28 1998-09-03 Warner Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
US6506798B1 (en) * 1997-07-01 2003-01-14 Warner-Lambert Company 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
US6821963B2 (en) * 1997-07-01 2004-11-23 Warner-Lambert Company 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
US6310060B1 (en) * 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
US6150359A (en) * 1997-08-20 2000-11-21 Warner-Lambert Company Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
NZ503788A (en) * 1997-10-27 2002-11-26 Agouron Pharma 4-aminothiazole derivatives and their use as inhibitors of cyclin-dependent kinases
US6262096B1 (en) * 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6242196B1 (en) * 1997-12-11 2001-06-05 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
CA2349832A1 (en) * 1999-01-13 2000-07-20 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
EP1144372B1 (en) * 1999-01-13 2005-11-30 Warner-Lambert Company Llc Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors
CA2355470C (en) * 1999-01-13 2008-09-30 Warner-Lambert Company Benzoheterocycles and their use as mek inhibitors
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
GB9910579D0 (en) * 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
WO2001044247A2 (en) * 1999-12-16 2001-06-21 Eli Lilly And Company Agents and methods for the treatment of proliferative diseases
SI1255752T1 (sl) * 2000-02-15 2007-12-31 Pharmacia & Upjohn Co Llc S pirolom substituirani zaviralci 2-indolinon protein kinaza
EP1339702A1 (en) * 2000-03-15 2003-09-03 Warner-Lambert Company 5-amide substituted diarylamines as mek inhibitors
GB0007371D0 (en) * 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
EP1295878B1 (en) * 2000-06-30 2004-09-15 Banyu Pharmaceutical Co., Ltd. Pyrazinone derivatives
DZ3401A1 (fr) * 2000-07-19 2002-01-24 Warner Lambert Co Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
ES2230337T3 (es) * 2000-09-01 2005-05-01 Glaxo Group Limited Derivados de oxindol.
TR200401316T4 (tr) * 2000-09-29 2004-07-21 Eli Lilly And Company Proliferatif hastalıkları tedavi etmek için yöntemler ve bileşikler
US20020197691A1 (en) * 2001-04-30 2002-12-26 Myriad Genetics, Incorporated FLT4-interacting proteins and use thereof
US6756374B2 (en) * 2001-01-22 2004-06-29 Hoffmann-La Roche Inc. Diaminothiazoles having antiproliferative activity
US7223388B2 (en) * 2001-08-03 2007-05-29 Board Of Regents, The Univeristy Of Texas System Modified reoviral therapy
ES2269793T3 (es) * 2001-10-30 2007-04-01 Novartis Ag Derivados de estaurospina como inhibidores de la actividad de tirosina quinasa receptora flt3.
CA2466762A1 (en) * 2001-12-04 2003-06-12 Onyx Pharmaceuticals, Inc. Raf-mek-erk pathway inhibitors to treat cancer
ATE302771T1 (de) * 2001-12-27 2005-09-15 Theravance Inc Indolinon-derivative als protein-kinasehemmer
ES2251677T3 (es) * 2002-01-22 2006-05-01 Warner-Lambert Company Llc 2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-onas.
EP1467968A1 (en) * 2002-01-23 2004-10-20 Warner-Lambert Company LLC N-(4-substituted phenyl)-anthranilic acid hydroxamate esters
DOP2003000556A (es) * 2002-01-23 2003-10-31 Warner Lambert Co Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
GB0205690D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
SG2013013339A (en) * 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
EP1482944A4 (en) * 2002-03-13 2006-04-19 Array Biopharma Inc NZ ALKYL BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS
US20040136975A1 (en) * 2002-03-22 2004-07-15 Duesbery Nicholas S Anthrax lethal factor inhibits tumor growth and angiogenesis
JP4588447B2 (ja) * 2002-08-09 2010-12-01 セラヴァンス， インコーポレーテッド 過剰増殖および関連疾患に関連するオンコキナーゼ融合ポリペプチド、これをコードする核酸、ならびにこれを検出する方法および同定する方法
CA2496164C (en) * 2002-08-23 2010-11-09 Chiron Corporation Benzimidazole quinolinones and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016069348A (ja) * 2014-09-30 2016-05-09 学校法人近畿大学 慢性骨髄性白血病の治療用組成物

Also Published As

Publication number Publication date
US20050171182A1 (en) 2005-08-04
EP1699477A2 (en) 2006-09-13
WO2005058341A2 (en) 2005-06-30
WO2005058341A3 (en) 2005-12-08

Similar Documents

Publication Publication Date Title
CN103998935B (zh) Hsp90组合疗法
CN118785911A (zh) 用于治疗肿瘤的药物组合物
US10183941B2 (en) Pyrimidine or pyridopyridone compound and application thereof
US9333205B2 (en) Isoxazolo-quinazolines as modulators of protein kinase activity
AU2004312049A1 (en) Treatment of malignant gliomas with TFG-beta inhibitors
US20170065609A1 (en) Anticancer agent composition
JP2019511564A (ja) アミノチアゾール化合物及びその使用
CA2934866A1 (en) Pharmaceutical combinations
EA024194B1 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
CN109562176A (zh) 使用静止细胞靶向和egfr抑制剂的用于治疗肿瘤的组合
CN110507654A (zh) 有酪氨酸激酶抑制剂的组合产品和其应用
JP2017193553A (ja) 神経線維腫症の処置のためのピリミジルアミノベンズアミド誘導体
CN118338905A (zh) Wee1激酶抑制剂在治疗癌症中的应用
JP2007513967A (ja) 変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物
KR20090034998A (ko) 알레르기성 질환과 같은 비만세포계 질병에 대한 ｎ-페닐-2-피리미딘아민의 용도
AU2016329513A1 (en) 2-Aminoquinazoline derivatives as p70S6 kinase inhibitors
CN101222850A (zh) 治疗对药物有抗性的癌症的方法
CN107406418B (zh) 4,5-二氢咪唑衍生物及其作为组蛋白脱甲基酶(kdm2b)抑制剂的用途
RU2445960C2 (ru) Применение производных пиримидиламинобензамида для лечения системного мастоцитоза
CN117479943A (zh) 组合疗法中的egfr抑制剂和perk活化剂及其用于治疗癌症的用途
CN105566329A (zh) 一种吡唑[5，6-d]并嘧啶类EGFR抑制剂及其抗肿瘤活性
Basso et al. Inhibition of cyclin-dependent kinases-A review of the recent patent literature
CN101360750A (zh) 应激活化蛋白激酶系统的调节方法
WO2024188129A1 (zh) 一种药用化合物在治疗实体瘤中的用途
HK40006457A (en) Hsp90 combination therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071205

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20100628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100707